FDA Clearance Tracker · DEN250032
LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261)
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Dec 23, 2025
De Novo granted
Time to decision
146 days
Received Jul 30, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN250032
- Device name
- LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261)
- Applicant
- DiaSorin, Inc.
- Applicant location
- Stillwater, MN
- Received
- Jul 30, 2025
- Decided
- Dec 23, 2025
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3176
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for DEN250032
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for DiaSorin, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260770 · Decided Jun 4, 2026 · 87 days after receipt
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM) · Laboratory Medicine & Pathology
P250039 · Decided May 7, 2026 · 220 days after receipt
Device type: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGM (MYM) · Laboratory Medicine & Pathology
P220034 · Decided Mar 29, 2024 · 458 days after receipt
Device type: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG (MYL) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.